<DOC>
	<DOCNO>NCT00930891</DOCNO>
	<brief_summary>Despite fact substantial response rate may obtain small-cell lung cancer ( use double-drug chemotherapy : cisplatin-etoposide , PE ) , cure remain exception . More aggressive regimen remain controversial recent attempt increase dose-intensity restrict patient favourable presentation . Bevacizumab humanize monoclonal antibody bind VEGF ( Vascular Endothelial Growth Factor ) . In association double-drug standard chemotherapy , proven bevacizumab improve survival previously untreated advanced non-small-cell lung cancer ( NSCLC ) , compare chemotherapy without bevacizumab ) . Such promising effect NSCLC deserve test small-cell lung cancer . In trial ( IFCT-0802 ) , standard chemotherapy ( PCDE PE ) compare experimental treatment ( PCDE PE + bevacizumab 7.5 mg/kg ) previously untreated SCLC patient .</brief_summary>
	<brief_title>Bevacizumab Extensive Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Inclusion Criteria ( must check inclusion , week 8 ) : SmallCell Lung Cancer histologically cytologically prove Extended disease define Veteran 's Administration Lung Cancer Group ( VALG ) At least one unidimensionally measurable lesion ( RECIST criterion ) Age 18 75 year Weight loss &lt; 10 % last three month Performance Status ( PS ) ≤ 2 Creatininemia &lt; 110 µmol/L creatinin clearance &gt; 60 mL/min Neutrophils ≥ 1,500/µL platelet ≥ 100,000/µL Bilirubin ≤ 1.5 x normal value Transaminases , Alkaline Phosphatase ≤ 2.5 x ULN except case liver metastasis ( 5xULN ) Left ventricular ejection fraction ( measure echocardiographic isotopic method ) &gt; 50 % PCDE plan Electrocardiogram without uncontrolled coronaropathy Signed informed consent Randomization Criteria ( check randomization ( week 0 ) ) : Partial complete tumoral response define RECIST All chemotherapyinduced toxicity decrease level ≤ 2 define NCI CTC VS 3 ( except alopecia ) Inclusion criterion concern creatininemia , clearance , neutrophil , platelet , transaminase , alkaline phosphatase leave ventricular ejection fraction must check NonSmallCell Lung Cancer mixed cancer ( smallcell / nonsmallcell ) Previous antitumoral treatment smallcell lung cancer ( chemotherapy , radiotherapy , immunotherapy , surgery ) Nonextended disease define VALG Natremia &lt; 125 mmol/L Hypercalcemia whereas corrective treatment Pathology contraindicate hyperhydration Hemoptysis last three month Tumor invade large vessel invade proximal tracheabronchial tree ( visible medical imagery ) . Investigator radiologist must reject tumor adjoin , merge extend large vessel 's lumen ( example : pulmonary artery , superior vena cava ) Symptomatic cerebral meningeal metastasis Other cancer progress medical history cancer five last year ( except basal cell carcinoma situ cervical cancer uterus . Important surgical intervention ( include surgical biopsy ) , traumatic lesion 28 day start treatment , anticipation important surgical intervention study Minor surgical intervention , include implant permanent catheter 24 hour first administration bevacizumab Unhealed wound , evolutive gastroduodenal ulcer , fracture bone Medical history abdominal fistula , tracheaoesophageal fistula , another type severity rank 4 , gastrointestinal perforation intraabdominal abscess 6 month inclusion Ongoing recent use aspirin ( 10 day first administration bevacizumab ) ( &gt; 325 mg/day ) use another platelet aggregation inhibitor ( dipyridamole , ticlopidine , clopidogrel &gt; 75 mg/day ) , ongoing recent use therapeutic dose ( 10 day first administration bevacizumab ) anticoagulant thrombolytic drug per o parenteral injection . Prophylactic use anticoagulant drug allow Medical history genetic predisposition bleed coagulopathy Clinically significative cardiac disease : infarct CVA 6 month inclusion , unstable angina , congestive cardiac failure level &gt; II define New York Heart Association ( NYHA ) cardiac arrythmia need specific treatment risk interfere study , uncontrolled arrythmia . Known allergy hypersensibility monoclonal antibody ( bevacizumab ) , chinese hamster ovary cell humanize recombinant antibody Uncontrolled high blood pressure ( systolic pressure &gt; 150 mm Hg and/or diastolic pressure &gt; 100 mm Hg ) , without hypotension treatment . Patients present high blood pressure eligibles treatment decrease blood pressure value require protocol . Severe ongoing infectious disease fever &gt; 38.5°C evidence pathology , organic neurologic function deterioration , physical examination laboratory result cause suspicion disease contraindicate use study treatment . Woman positive pregnancy test make pregnancy test ( unless pregnancy risk exclude ) Lactating woman Sexually active woman n't use hormonal mechanical contraceptive method sexually active man sexually active partner n't want use effective contraceptive method course study 6 month last treatment administration Patient already include treated present study Patient participate participate another study 4 week treatment administration Patient receive previous antiangiogenic treatment ( experimental commercial : bevacizumab , thalidomide , CP547632 , sunitinib , sorafenib ... ) Geographical psychological condition allow good comprehension compliance protocol Liberty deprive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Extensive-Disease Small-Cell Lung Cancer</keyword>
</DOC>